シスプラチン炭酸塩複合体 シスプラチン炭酸塩複合体 吸収への影響,抗腫瘍特性,毒性
Corey R Centerwall1, Jerry Goodisman, Deborah J Kerwood
1Department of Chemistry, Syracuse University, CST 1-014, Syracuse, New York 13244-4100, USA.
Journal of the American Chemical Society
|September 15, 2005
まとめ
シスプラチンは,生物学的液体の炭酸と反応し,モノクロとビスカルボナート複合体を形成する. これらの種はシスプラチンに影響を及ぼす可能性があります.
科学分野:
- 無機化学 無機化学とは
- 薬用化学 薬用化学について
- バイオケミストリー バイオケミストリー
背景:
- シスプラチン (Cisplatin) は,広く使用されているプラチナベースの化学療法薬です.
- 培養媒介と血液には炭酸イオンが含まれています.
- 生物環境におけるシスプラチンの反応性を理解することは極めて重要です.
研究 の 目的:
- 水性シスプラチンと炭酸塩の反応製品を調査する.
- 生理学的条件下で炭酸塩種の形成を特徴付ける.
- これらの種がシスプラチンの治療効果に与える潜在的な影響を調査する.
主な方法:
- 水性シスプラチンと炭酸塩の反応動態を研究した.
- 形成された中間複合体と最終複合体を特徴づけた.
- がん治療に関連する生理学的条件をシミュレートする.
主要な成果:
- 初期反応はモノクロモノカルボナートシスプラチン種を産生する.
- 炭酸に長時間曝露すると,ビスカーボナート複合体の形成が起こります.
- これらの炭酸塩複合体は,シミュレートされた治療条件下で形成されます.
結論:
- 炭酸塩種の形成は,生物学的媒介におけるシスプラチンにとって重要な反応経路である.
- これらの種は,シスプラチンの細胞の吸収と分布に影響を与える可能性があります.
- 変異種はシスプラチンの抗腫瘍活性と毒性プロファイルに影響を与える可能性があります.
関連する概念動画
Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


